Ethambutol (as part of an optimized background regimen for MDR-TB)
Treatment for Hiv Aids Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: 15-25mg/kg daily
Effectiveness
65%
Safety Score
70%
Clinical Trials
60
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
15-25mg/kg daily
Time to Effect
2-4 months for clinical improvement
Treatment Duration
Ethambutol component 6-12 months, total regimen 9-18 months
Evidence Quality
MODERATENumber Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$11,000
Monitoring:$1,000
Side Effect Mgmt:$500
Total Annual:$12,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
6
Outcome-Based Costs
Cost per Responder
$19,231
Cost per Remission
$19,231
Comparison vs Regimens without Ethambutol (if susceptible)
Cost Difference
$-3,000/year
Less expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Prescription Access Economics
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWRequires Monitoring
YesNeeds lab work/checkups
Ethambutol (as part of an optimized background regimen for MDR-TB) Outcomes
for Hiv Aids Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+65%
Remission Rate
+65%
Common Side Effects
Optic neuritis (decreased visual acuity, red-green color blindness)
+3%
Hyperuricemia
+15%
Peripheral neuropathy
+0.5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov